Kapitel 79: Myelodysplastische Syndrome


Andersen MK, Christiansen DH, Kirchhoff M et al. (2001) Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and ANL, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 31: 33–41


Bernasconi C, Alessandrino EP, Bernasconi P et al. (1998) Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high risk myelodysplastic or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 102: 678–683


Christiansen DH, Andersen MK, Pedersen-Bjergaard J. (2004) Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 104: 1474–1481
De Witte T, Suciu S, Peetermans M et al. (1995a) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9: 1805–1811
De Witte T, Suciu S, Boogaerts M et al. (1995b) Intensive remission-induction chemotherapy followed by autologous or allogenic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (sAML) in patients <60 years. A joint study of the EORTC LCG and the EBMT (abstract). Blood 86 [Suppl 1]: 618a

de for Me, Demuyck H, Vandenberghe P et al. (1995) Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 86: 3660–3667


Estey EH, Thall PF, Giles FJ et al. (2002) Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukaemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, highdose cytosine arabinoside. Blood 99: 4343–4349


Germing U, Hildebrandt B, Pfeilstöcker M et al. (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19: 2223–2231


Horike S, Misawa S, Nakai H et al. (1994) N-Ras mutation and karyotype evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 8: 1331–1336


Hoyle CF, De Bastos M, Wheatley K et al. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: Results from the MRC’s 9th AML trial. Br J Haematol 72: 45–53


Ingram W, Lea NC, Cervera J (2006) The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 20: 1–3
Keating MJ, McCredie KB, Benjamin RS et al. (1981) Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 58: 584–591
Kiladjian JJ, Bourgeois E, Lobe I et al. (2006) Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 20: 463–470
Kröger N, Shimoni, A, Zabelina T et al. (2006) Reduced-toxicity conditioning with treosulfan, fludarabin and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS) Bone Marrow Transplantat 37: 339–344


Michels SD, McKenna RW, Arthur DC et al. (1985) Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood 65: 1365‒1372


Mihara K, Chowdhury M, Nakaju N et al. (2006) Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndromes and prognosis of the patients. Cancer 64: 305‒308


Morel P, Hebbar M, Lai J et al. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7: 1315‒1323


Oosterveld M, Suciuc S, Verhoef G et al. (2003) The presence of an HLA-identical sibling donor has no impact on outcome of patients with highrisk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 17: 859–868


Raza A, Qwawi H, Lisak L et al. (2000) Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95: 1580–1587


Rowinsky EK, Conley BA, Jones RJ et al. (1992) Hexamethylen bisacetamide in myelodysplastic syndrome: Effect of five-day exposure to maximal therapeutic concentrations. Leukemia 6: 526–534


Saunthararajah Y, Nakamura R, Nam JM et al. (2002) HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromes. Blood 100: 1570–1574.


Silverman LR, Davis RB, Holland JF et al. (1989) 5-Azacytidine (AZ) as a low-dose continuous infusion is an effective therapy of patients with myelodysplastic syndromes (MDS). Blood 73: 263–270.


Tauro S, Craddock C, Peggs K et al. (2005) Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23: 9387‒9393


Wattel E, Solary E, Cailiot D et al. (1995) Intensive chemotherapy (CT) with or without quinine followed by autologous BMT in myelodysplastic syndromes (MDS) and secondary leukemia (SL). Preliminary results of a randomized trial (abstract). Blood 86 [Suppl 1]: 804a


Wattel E, Solary E, Leleu X et al. (1999) A prospective trial of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia 13: 524–529


Wijermans PW, Lübbert M, Verhoef G et al. (2005) An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 84: 9–17


